Company news

CG Oncology, Inc. news in 2026

CG Oncology, Inc.'s news releases, calls and decks from 2026, newest first.

View company

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

October 13, 2026

CG Oncology to Present at Upcoming Investor Conferences in September

September 2, 2026

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

July 27, 2026

CG Oncology to Present at Upcoming Investor Conferences in June

May 28, 2026

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

May 18, 2026

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

May 15, 2026

CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

May 11, 2026

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026

CG Oncology to Present at Upcoming Investor Conferences in May

May 5, 2026

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

February 27, 2026

CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

February 22, 2026

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

January 14, 2026

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

January 9, 2026

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026